Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of JR-141 (Idursulfase) in Patients With Mucopolysaccharidosis Type II

Trial Profile

A Phase I/II Study of JR-141 (Idursulfase) in Patients With Mucopolysaccharidosis Type II

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Dec 2018

At a glance

  • Drugs Idursulfase (Primary)
  • Indications Mucopolysaccharidosis II
  • Focus Adverse reactions; First in man
  • Sponsors JCR Pharmaceuticals
  • Most Recent Events

    • 21 Dec 2018 Results published in the published in the electronic edition of Molecular Therapy, the official journal of The American Society of Gene & Cell Therapy.
    • 21 Dec 2018 Results published in a JCR Pharmaceuticals media release.
    • 21 Dec 2018 According to a JCR Pharmaceuticals media release,the company announced that the results of this study have been published in the electronic edition of Molecular Therapy,the official journal of The American Society of Gene & Cell Therapy (ASGCT).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top